The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Key therapeutic areas
Autoimmune disorders
Cardiovascular diseases
Genetic disorders
Hematological disorders
Metabolic disorders
Ophthalmic disorders
Oncological disorders
Others
- Type of vector
- Adeno associated virus
- Adenovirus
- Herpes simplex virus type 1
- Lentivirus
- Plasmid DNA
- Retrovirus
- Vaccinia Virus
Type of therapy
- Ex vivo
- In vivo
Type of gene modification
- Gene augmentation
- Immunotherapy
- Oncolytic therapy
- Others
Route of administration
- Intraarticular
- Intracerebellar
- Intramuscular
- Intradermal
- Intravenous
- Intravitreal
- Intravesical
- Subretinal
- Others
Key geographical regions
North America
Europe
Asia-Pacific
The report includes detailed transcripts of discussions held with the following experts:
- Adam Rogers (CEO, Hemera Biosciences)
- Al Hawkins (CEO, Milo Biotechnology)
- Buel Dan Rodgers (Founder & CEO, AAVogen)
- Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
- Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)
- Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)
- Jeffrey Hung (CCO, Vigene Biosciences)
- Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
- Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
- Robert Jan Lamers (CEO, Arthrogen)
- Tom Wilton (Chief Business Officer, LogicBio Therapeutics)
To request sample pages, please visit this – https://www.rootsanalysis.com/reports/268/request-sample.html
Key Questions Answered
- Who are the leading industry players in this market?
- How big is the development pipeline and which new indications are coming in focus? Which vectors are being used for effective delivery of the therapeutic agents?
- Who are the key investors in the gene therapy market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What kind of commercialization strategies are being adopted by gene therapy developers?
- What are the different pricing models and reimbursement strategies used for gene therapies?
- What are the prevalent R&D trends related to gene therapies?
- What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
- Who are the key CMOs / CDMOs that claim to supply viral / plasmid vectors for gene therapy development?
You may also be interested in the following titles:
- Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
- CAR-T Therapies Market (2nd Edition), 2019-2030
- Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
